Hamid R. Okhravi

Hamid R. Okhravi

Geriatrics | Internal Medicine

825 Fairfax Ave, Hofheimer Hall
Ste 201
Norfolk, VA 23507

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Machine learning-enhanced non-amnestic Alzheimer's disease diagnosis from MRI and clinical features.

Machine learning-enhanced non-amnestic Alzheimer's disease diagnosis from MRI and clinical features.

Journal: ArXiv

Published: February 06, 2026

Effect of antipsychotic medication use and type on mortality and cardiovascular risks in nursing home patients with dementia.

Effect of antipsychotic medication use and type on mortality and cardiovascular risks in nursing home patients with dementia.

Journal: Alzheimer's & dementia (Amsterdam, Netherlands)

Published: April 15, 2025

System readiness and the patient care pathway for Alzheimer's disease diagnosis and treatment.

System readiness and the patient care pathway for Alzheimer's disease diagnosis and treatment.

Journal: Alzheimer's & dementia (New York, N. Y.)

Published: December 11, 2024

Escitalopram for agitation in Alzheimer's dementia: a randomized controlled phase 3 trial.

Escitalopram for agitation in Alzheimer's dementia: a randomized controlled phase 3 trial.

Journal: Nature medicine

Published: July 01, 2024

Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial.

Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial.

Journal: JAMA neurology

Published: April 29, 2024

Functionally distinct pericyte subsets differently regulate amyloid-β deposition in patients with Alzheimer's disease.

Functionally distinct pericyte subsets differently regulate amyloid-β deposition in patients with Alzheimer's disease.

Journal: Brain pathology (Zurich, Switzerland)

Published: February 05, 2024

Benefits and risks of FDA-approved amyloid-targeting antibodies for treatment of early Alzheimer's disease: Navigating clinician-patient engagement.

Benefits and risks of FDA-approved amyloid-targeting antibodies for treatment of early Alzheimer's disease: Navigating clinician-patient engagement.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association

Published: January 22, 2024

Utility of amyloid PET Imaging in a Memory Clinic.

Utility of amyloid PET Imaging in a Memory Clinic.

Journal: Alzheimer disease and associated disorders

Published: April 24, 2023

Atypical Case of VV1 Creutzfeldt-Jakob Disease Subtype: Case Report.

Atypical Case of VV1 Creutzfeldt-Jakob Disease Subtype: Case Report.

Journal: Frontiers in neurology

Published: February 14, 2022

Sleep in Alzheimer's disease: a systematic review and meta-analysis of polysomnographic findings.

Sleep in Alzheimer's disease: a systematic review and meta-analysis of polysomnographic findings.

Journal: Translational psychiatry

Published: December 13, 2021

Discordance Between Cerebrospinal Fluid Biomarkers and Amyloid Positron Emission Tomography in Alzheimer's Sheds Light on Clinical Trial Exclusion Criteria.

Discordance Between Cerebrospinal Fluid Biomarkers and Amyloid Positron Emission Tomography in Alzheimer's Sheds Light on Clinical Trial Exclusion Criteria.

Journal: Cureus

Published: March 29, 2021

A subtype of cerebrovascular pericytes is associated with blood-brain barrier disruption that develops during normal aging and simian immunodeficiency virus infection.

A subtype of cerebrovascular pericytes is associated with blood-brain barrier disruption that develops during normal aging and simian immunodeficiency virus infection.

Journal: Neurobiology of aging

Published: June 24, 2020

Showing 1-12 of 16

Last Updated: 09/26/2026